

INTERNATIONAL CONFERENCE ON
OPIOIDS

June 11-13, 2017

Joseph B. Martin Conference Center
at Harvard Medical School
Boston, Massachusetts, USA

OPIOIDS IN PAIN MANAGEMENT: THE FUSION OF SCIENCE AND PRACTICE

Keynotes



Kana Enomoto

Kana Enomoto

Principal Deputy Administrator
Office of the Administrator
Substance Abuse and Mental Health Services Administration

Ms. Enomoto has been delegated the functions, duties, and authorities of the Administrator of The Substance Abuse and Mental Health Services Administration (SAMHSA). Ms. Enomoto oversees an agency with four centers and four offices, over 600 employees, and a budget of \$3.7 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency's mission to reduce the impact of substance abuse and mental illness on America's communities.



Lynn R. Webster, MD

Lynn R. Webster, MD, FACPM, FASAM

Vice President of Scientific Affairs
PRA Health Sciences
Past President, American Academy of Pain Medicine (AAPM)

Dr. Webster has dedicated more than three decades to becoming an expert in the field of pain management. A leading voice in trying to help physicians safely treat pain patients, Dr. Webster actively works within the industry to develop safer and more effective therapies for chronic pain and addiction. Dr. Webster lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients and has authored more than 300 scientific abstracts, manuscripts, journal articles and a book entitled *Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners*.



Sharon Walsh, PhD

Sharon Walsh, PhD

Professor, Department of Behavioral Science and Psychiatry
Director of the Center on Drug and Alcohol Research
College of Medicine, University of Kentucky

Dr. Walsh's clinical research is focused on pharmacological issues in opioid and cocaine dependence and has been supported by the National Institute on Drug Abuse, private foundations and the pharmaceutical industry. She has conducted studies on the pharmacodynamic and pharmacokinetic characteristics of opioid treatment agents, including buprenorphine, methadone, LAAM and lofexidine, has conducted abuse liability evaluations of opioid analgesics and has evaluated potential pharmacotherapies for efficacy and safety in the treatment of cocaine dependence.

ICOO 2017

For more details visit:
www.opioidconference.org



Join Us in Boston. Register Today.
www.opioidconference.org

